Top Page
Dimerix Limited
(Sydney:DXB)
Dimerix Limited (DXB) vs. S&P 500 (SPY)
Dimerix Limited Business Overview & Revenue Model
Dimerix Limited Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 737.87K | 583.48K | 8.98M | 6.46M | 4.44M | 2.34M | Gross Profit |
| 737.87K | 583.48K | 8.93M | 6.41M | 4.40M | 2.33M | EBIT |
| -31.39M | -25.06M | -22.82M | -16.96M | -10.93M | -6.92M | EBITDA |
| -23.45M | -24.96M | -22.68M | -16.47M | -10.02M | -6.82M | Net Income Common Stockholders |
| -23.31M | -17.08M | -13.80M | -10.49M | -6.37M | -4.49M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 21.11M | 22.14M | 7.99M | 9.63M | 5.25M | 7.79M | Total Assets |
| 21.91M | 32.08M | 17.76M | 16.50M | 9.42M | 10.39M | Total Debt |
| 156.42K | 149.68K | 5.96M | 73.10K | 5.04M | 1.06M | Net Debt |
| -20.96M | -21.99M | -2.03M | -9.56M | -207.00K | -6.73M | Total Liabilities |
| 14.74M | 13.89M | 11.79M | 2.07M | 7.95M | 2.63M | Stockholders Equity |
| 7.17M | 18.19M | 5.96M | 14.42M | 1.47M | 7.76M |
| Cash Flow | Free Cash Flow | ||||
| -18.80M | -7.02M | -12.73M | -13.45M | -6.47M | -4.72M | Operating Cash Flow |
| -18.78M | -7.00M | -12.73M | -13.44M | -6.46M | -4.72M | Investing Cash Flow |
| -24.96K | -15.80K | -2.30K | -10.61K | 4.38K | 0.00 | Financing Cash Flow |
| 25.35M | 21.41M | 11.07M | 17.69M | 3.93M | 8.91M |
Dimerix Limited Technical Analysis
Dimerix Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | AU$54.32M | 110.00 | -8.34% | ― | -5.27% | 50.29% | |
63 Neutral | $8.79B | 172.19 | 14.52% | ― | 55.85% | 893.42% | |
56 Neutral | AU$40.27M | ― | -36.95% | ― | ― | 11.11% | |
54 Neutral | AU$251.04M | ― | -37.20% | ― | ― | 32.02% | |
52 Neutral | $5.15B | 3.02 | -44.64% | 2.83% | 16.44% | -0.47% | |
50 Neutral | AU$344.28M | ― | -524.68% | ― | 322.26% | -53.98% |
Dimerix Limited Corporate Events
Dimerix Limited has announced the issuance of 12,350,583 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing development projects, potentially impacting its market position and offering opportunities for stakeholders.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.36 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced the quotation of 1,808,257 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code DXB. This move is part of the company’s strategic efforts to enhance its market presence and potentially increase its shareholder base, reflecting its ongoing commitment to growth and expansion in the biotechnology sector.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.36 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced the quotation of 948,636 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code DXB. This move follows the exercise of options or conversion of other convertible securities, potentially enhancing the company’s liquidity and market presence.
Dimerix Limited has announced the quotation of 3,474,780 fully paid ordinary securities on the ASX, following the exercise of options or conversion of convertible securities. This move is part of the company’s ongoing efforts to enhance its market presence and provide liquidity to its stakeholders, potentially impacting its operational capabilities and industry positioning.
Dimerix Limited has received an initial payment of US$30 million from Amicus Therapeutics as part of a licensing agreement for the commercialization of DMX-200 in the United States. This agreement, along with others, positions Dimerix to potentially earn up to AU$1.4 billion in upfront and milestone payments, plus royalties, significantly enhancing its financial and operational capabilities to advance DMX-200 as a treatment for FSGS. The company retains rights to DMX-200 in territories not covered by existing agreements and continues to seek additional licensing opportunities.
Dimerix Limited has announced the quotation of 581,561 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code DXB, effective May 1, 2025. This move reflects the company’s ongoing efforts to enhance its market presence and provide additional liquidity for its stakeholders.
Dimerix Limited announced a US licensing transaction for their Phase 3 clinical asset, DMX-200, aimed at treating Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease. The company is hosting an investor webinar to discuss this development and the progress of their clinical trials. This move is significant for Dimerix as it could enhance their market positioning by addressing an unmet medical need and potentially securing market exclusivity through Orphan Drug Designation incentives in the US and Europe.
Dimerix Limited and Amicus Therapeutics have entered into an exclusive license agreement for the commercialization of Dimerix’s Phase 3 drug candidate DMX-200 in the United States. This agreement grants Amicus the rights to commercialize DMX-200 for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease with no FDA-approved therapies, while Dimerix retains commercialization rights outside the U.S. The deal includes an upfront payment of US$30 million to Dimerix, with potential milestone payments and royalties based on sales and development achievements. This collaboration is expected to enhance Dimerix’s market positioning by leveraging Amicus’s regulatory and commercial expertise, potentially transforming treatment options for FSGS patients.
Dimerix Limited announced significant progress in its quarterly activities report, highlighting a positive meeting with the FDA that confirmed proteinuria as an acceptable endpoint for marketing approval of DMX-200 in the US. The company also secured a development and license agreement with Fuso Pharmaceutical Industries for DMX-200 in Japan, potentially worth up to ¥10.5 billion, and continued to receive strong partnering interest globally. These developments, alongside its inclusion in the S&P ASX All Ordinaries, position Dimerix favorably in the biopharmaceutical industry, with potential implications for stakeholders through expanded market reach and financial growth.
Dimerix Limited has announced the issuance of 20,250 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX) under the code DXB as of April 28, 2025. This move reflects the company’s ongoing efforts to strengthen its financial position and enhance its market presence, potentially impacting its operational capabilities and investor relations positively.
Dimerix Limited announced a significant development in its Phase 3 clinical trial for DMX-200, as the FDA confirmed proteinuria as an acceptable primary endpoint for full marketing approval in the US for treating Focal Segmental Glomerular Sclerosis (FSGS). This decision aligns with Dimerix’s previous clinical findings and could potentially expedite the drug’s market entry, offering hope for patients with this progressive disease.
Dimerix Limited has announced the issuance of 13,125 ordinary fully paid securities, which will be quoted on the Australian Securities Exchange (ASX) under the code DXB. This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing development projects, potentially strengthening its market position and offering new opportunities for stakeholders.
Dimerix Limited announced the quotation of 152,501 new ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code DXB. This move reflects the company’s ongoing efforts to enhance its capital structure and potentially improve its market positioning, offering stakeholders an opportunity to engage with the company’s growth trajectory.
Dimerix Limited announced its participation in the ASX CEO Connect event, highlighting its Phase 3 clinical asset in kidney disease. The company is working on DMX-200, which has shown promising results in addressing the unmet medical needs of FSGS, a rare and severe kidney disease. With Orphan Drug Designation in the US and Europe, Dimerix is poised for potential market exclusivity and accelerated regulatory pathways, which could significantly impact its market position and offer new hope for patients with limited treatment options.
Dimerix Limited has announced the quotation of 5,000 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code DXB, effective April 10, 2025. This move reflects the company’s ongoing efforts to enhance its financial flexibility and strengthen its market presence, potentially benefiting stakeholders by increasing liquidity and visibility in the market.
Dimerix Limited has updated its Securities Trading Policy to align with current listing rules, reflecting its ongoing commitment to regulatory compliance. This update comes as the company continues to advance its Phase 3 clinical asset in kidney disease, potentially impacting its market operations and stakeholder interests.
Dimerix Limited has announced the quotation of 5,352 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of April 4, 2025. This move is part of the company’s strategy to enhance its capital structure and potentially improve its market positioning, which could have implications for its stakeholders by increasing liquidity and potentially attracting more investors.
Dimerix Limited announced the quotation of 12,000 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code DXB, effective April 2, 2025. This move is part of the company’s strategic efforts to enhance its financial flexibility and support its ongoing research and development initiatives, potentially impacting its market positioning and stakeholder interests positively.
Dimerix Limited announced that its CEO, Dr. Nina Webster, will present at the HealthInvest Summit 2025 in Sydney, highlighting the status of its ACTION3 Phase 3 clinical trial for FSGS kidney disease. The presentation will also cover updates from a recent FDA meeting and discuss the commercial potential of their therapies. This announcement underscores Dimerix’s strategic focus on addressing unmet medical needs in the kidney disease market, potentially strengthening its position in the biopharmaceutical industry and offering significant implications for stakeholders, given the lack of approved treatments for FSGS.
Dimerix Limited has announced the quotation of 84,167 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code DXB. This move signifies the company’s ongoing efforts to enhance its financial standing and operational capabilities, potentially impacting its market position and stakeholder interests positively.
Dimerix Limited has announced the application for quotation of 98,301 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective from March 25, 2025. This move reflects the company’s ongoing efforts to enhance its financial flexibility and potentially strengthen its market position by increasing its capital base, which could have implications for its growth strategy and stakeholder interests.
Dimerix Limited has announced the quotation of 2,599 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code DXB. This move is part of the company’s ongoing efforts to enhance its financial flexibility and strengthen its market position, potentially impacting its operational capabilities and providing value to its stakeholders.
Dimerix Limited has announced the quotation of 23,278 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code DXB, effective March 14, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing development projects, potentially strengthening its position in the biotechnology sector and offering new opportunities for stakeholders.
Dimerix Limited announced that its CEO, Dr. Nina Webster, will present at the Euroz Hartleys Institutional Conference, highlighting the company’s progress in developing DMX-200, a Phase 3 clinical asset for kidney disease. The announcement underscores Dimerix’s strategic positioning in addressing unmet medical needs in the kidney disease market, particularly with its focus on FSGS, a rare and severe condition with limited treatment options. The company’s efforts are bolstered by Orphan Drug Designation in the US and Europe, which provides incentives for developing treatments for rare diseases.
Dimerix Limited has announced the quotation of 1,000 new fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code DXB, effective from March 6, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing development projects, potentially impacting its market position and offering new opportunities for stakeholders.
Dimerix Limited has received an initial payment of ¥300 million from FUSO Pharmaceutical Industries as part of a licensing agreement for the commercialization of DMX-200 in Japan. This agreement, along with others with Advanz Pharma and Taiba, positions Dimerix to potentially receive up to AU$458 million in payments and royalties, supporting the advancement of DMX-200 as a treatment for FSGS. The company is also focusing on expanding its licensing agreements in major markets such as the US and China.
Dimerix Limited has announced the quotation of 147,275 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code DXB, effective March 3, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support ongoing development projects, potentially strengthening its position in the biotechnology market.
Dimerix Limited announced the quotation of 33,084 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code DXB, following the exercise of options or conversion of convertible securities. This move is part of Dimerix’s ongoing efforts to bolster its financial standing and enhance its operational capacity, potentially strengthening its position in the biotech industry and benefiting stakeholders.